NATCO Pharma Limited (IN:NATCOPHARM)
:NATCOPHARM
Want to see IN:NATCOPHARM full AI Analyst Report?
NATCOPHARM Stock Chart & Stats
₹893.35
-₹7.80(-0.59%)
At close: 4:00 PM EST
₹893.35
-₹7.80(-0.59%)
Day’s Range― - ―
52-Week Range₹752.10 - ₹1,134.90
Previous CloseN/A
Volume335.92K
Average Volume (3M)59.22K
Market Cap
₹195.89B
Enterprise Value₹197.45B
Total Cash (Recent Filing)₹40.77B
Total Debt (Recent Filing)₹2.61B
Price to Earnings (P/E)26.7
Beta1.04
Next Earnings
Jun 01, 2026EPS Estimate
15.76Next Dividend Ex-DateN/A
Dividend Yield0.57%
Share Statistics
EPS (TTM)8.43
Shares Outstanding179,109,860
10 Day Avg. Volume63,709
30 Day Avg. Volume59,218
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)1.90
Price to Sales (P/S)3.25
P/FCF Ratio10.10
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)39.96
Revenue Forecast (FY)₹32.11B
Bulls Say, Bears Say
Bulls Say
High Profitability MarginsSustained, very high EBITDA/EBIT and net margins indicate durable operating leverage and pricing power in complex or differentiated products. High margins give flexibility to fund R&D, regulatory filings and commercial launches, and provide a cushion against pricing pressure over months.
Strong Free Cash Flow GenerationLarge FCF growth and near‑one conversion of profits to cash signal reliable cash generation from operations. This strengthens the firm's ability to fund capex, pay suppliers, and support commercialization without heavy external financing over the medium term.
Very Low Leverage And High ROEMinimal financial leverage reduces solvency and refinancing risk while a strong ROE shows efficient capital use. This combination supports investment capacity and resilience to shocks, enabling strategic investment in complex generics and manufacturing over the coming months.
Bears Say
Declining Gross Profit NotedA reported decline in gross profit suggests margin pressure at the cost-of-goods or pricing level. If structural (input cost inflation, competitive pricing or product mix shifts), continued erosion could reduce the current high margin buffer and impair reinvestment ability.
Capex And Liabilities Need AttentionRising liabilities or higher capex requirements can drain free cash flow and force external funding or slower payout/investment. Over a multi-month horizon, elevated capex or liability growth could constrain flexibility despite strong operating cash flows.
Negative EPS GrowthA negative EPS growth rate despite revenue expansion signals earnings volatility or non-operating impacts that reduce per-share earnings. Persistent EPS decline could undermine confidence in sustainable earnings power and affect capital allocation decisions.
NATCO Pharma Limited News
NATCOPHARM FAQ
What was NATCO Pharma Limited’s price range in the past 12 months?
NATCO Pharma Limited lowest stock price was ₹752.10 and its highest was ₹1134.90 in the past 12 months.
What is NATCO Pharma Limited’s market cap?
NATCO Pharma Limited’s market cap is ₹195.89B.
When is NATCO Pharma Limited’s upcoming earnings report date?
NATCO Pharma Limited’s upcoming earnings report date is Jun 01, 2026 which is in 31 days.
How were NATCO Pharma Limited’s earnings last quarter?
NATCO Pharma Limited released its earnings results on Feb 12, 2026. The company reported ₹8.43 earnings per share for the quarter, beating the consensus estimate of ₹5.267 by ₹3.163.
Is NATCO Pharma Limited overvalued?
According to Wall Street analysts NATCO Pharma Limited’s price is currently Overvalued.
Does NATCO Pharma Limited pay dividends?
NATCO Pharma Limited pays a Quarterly dividend of ₹1.5 which represents an annual dividend yield of 0.57%. See more information on NATCO Pharma Limited dividends here
What is NATCO Pharma Limited’s EPS estimate?
NATCO Pharma Limited’s EPS estimate is 15.76.
How many shares outstanding does NATCO Pharma Limited have?
NATCO Pharma Limited has 179,109,860 shares outstanding.
What happened to NATCO Pharma Limited’s price movement after its last earnings report?
NATCO Pharma Limited reported an EPS of ₹8.43 in its last earnings report, beating expectations of ₹5.267. Following the earnings report the stock price went down -1.275%.
Which hedge fund is a major shareholder of NATCO Pharma Limited?
Currently, no hedge funds are holding shares in IN:NATCOPHARM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
NATCO Pharma Limited
NATCO Pharma Limited, a pharmaceutical company, develops, manufactures, and markets finished dosage formulations and active pharmaceutical ingredients (APIs). It offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, ovary, etc.; and APIs in various categories, such as oncology, central nervous system, pain management, and CV care. The company also offers orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, it provides cardiology and diabetology products for the treatment of hypertension, stable angina and CHF. The company markets its products in approximately 40 countries, including India, the United States, and internationally. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India.
Technical Analysis
Glenmark Pharmaceuticals Limited
―
―
Jubilant Pharmova Limited
―
Marksans Pharma Limited
―
Rainbow Childrens Medicare Limited
―